Review of in vitro activity of third-generation cephalosporins and other newer XXXX antibiotics against clinically important bacteria.

@entity5503 @entity3256 @entity796 @entity3405 @entity794 @entity5821 @entity2886 @entity6728 @entity581 @entity8933 @entity2891 @entity5505 @entity3398 @entity3399
The third-generation cephalosporins and some newer @entity3405 compounds such as the monobactams and carbapenems, when compared with first- and second-generation cephalosporins, have an extended spectrum of activity and generally greater activity against gram-negative bacilli of clinical importance. The increased spectrum includes the Enterobacteriaceae and @entity796 . Although the third-generation cephalosporins have some activity against @entity796 , of those drugs now available in the United States, @entity5505 and @entity2891 are much more active than the others, and @entity5505 is more active than @entity2891 . The activity of the third-generation compounds against Acinetobacter species and other @entity796 species is limited. These compounds inhibit the growth of @entity6728 and Neisseria species (including beta-lactamase-producing isolates), nonenterococcal streptococci, and anaerobic gram-positive cocci. They also inhibit the growth of @entity3256 -susceptible @entity794 and coagulase-negative staphylococci but generally are not as active against these organisms as are the first-generation cephalosporins. They do not inhibit @entity3256 -resistant @entity794 . The activity of third-generation cephalosporins against anaerobes varies, but @entity3399 and @entity8933 are similar in activity to @entity3398 , a second-generation compound. The third-generation @entity2886 do not inhibit the growth of Listeria. A majority of organisms resistant to @entity5821 and @entity5503 (first- and second-generation cephalosporins) and to @entity581 are inhibited by third-generation cephalosporins.
